Details of the Drug

General Information of Drug (ID: DM4L6EU)

Drug Name
Trandolapril
Synonyms
Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [1]
Hypertension BA00-BA04 Approved [2]
Malignant essential hypertension BA00 Approved [1]
Therapeutic Class
Antihypertensive Agents
Affected Organisms
Humans and other mammals
ATC Code
C09AA10: Trandolapril
C09AA: ACE inhibitors, plain
C09A: ACE INHIBITORS, PLAIN
C09: AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 430.5
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption
The absorption of drug is 40-60% []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12.5 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 10 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.0618 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.17% [4]
Vd
The volume of distribution (Vd) of drug is 18 L []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Blood pressure decreased Not Available ACE OTDF1964 [6]
Cough Not Available BDKRB2 OTOA9D3W [6]
Chemical Identifiers
Formula
C24H34N2O5
IUPAC Name
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
Canonical SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O
InChI
InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
InChIKey
VXFJYXUZANRPDJ-WTNASJBWSA-N
Cross-matching ID
PubChem CID
5484727
ChEBI ID
CHEBI:9649
CAS Number
87679-37-6
UNII
1T0N3G9CRC
DrugBank ID
DB00519
TTD ID
D0M5OC
VARIDT ID
DR00240
INTEDE ID
DR2657
ACDINA ID
D00695
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [8]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Drug Response [6]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Drug Response [6]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic heart failure
ICD Disease Classification BD1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Peptide transporter 2 (SLC15A2) DTP PEPT2 8.33E-02 -3.63E-02 -1.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trandolapril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eprosartan DM07K2I Major Increased risk of hyperkalemia by the combination of Trandolapril and Eprosartan. Hypertension [BA00-BA04] [10]
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Trandolapril and Aliskiren. Hypertension [BA00-BA04] [11]
Losartan DM72JXH Major Increased risk of hyperkalemia by the combination of Trandolapril and Losartan. Hypertension [BA00-BA04] [10]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Trandolapril and Doxazosin. Hypertension [BA00-BA04] [12]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Trandolapril and TAK-491. Hypertension [BA00-BA04] [10]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Trandolapril and Indapamide. Hypertension [BA00-BA04] [13]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Trandolapril and Trichlormethiazide. Hypertension [BA00-BA04] [13]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Trandolapril and Telmisartan. Hypertension [BA00-BA04] [10]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Trandolapril and Irbesartan. Hypertension [BA00-BA04] [14]
Hydrochlorothiazide DMUSZHD Moderate Additive hypotensive effects by the combination of Trandolapril and Hydrochlorothiazide. Hypertension [BA00-BA04] [13]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Trandolapril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Trandolapril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [16]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Repaglinide. Acute diabete complication [5A2Y] [17]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Glibenclamide. Acute diabete complication [5A2Y] [17]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Tolazamide. Acute diabete complication [5A2Y] [17]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Insulin-glulisine. Acute diabete complication [5A2Y] [17]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Insulin-aspart. Acute diabete complication [5A2Y] [18]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Glipizide. Acute diabete complication [5A2Y] [17]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Trandolapril and Isosorbide dinitrate. Anal fissure/fistula [DB50] [19]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Trandolapril and Linezolid. Bacterial infection [1A00-1C4Z] [21]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Trandolapril and Cariprazine. Bipolar disorder [6A60] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Trandolapril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [23]
Mannitol DMSCDY9 Moderate Additive hypotensive effects by the combination of Trandolapril and Mannitol. Bronchiectasis [CA24] [13]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Trandolapril and Olopatadine. Conjunctiva disorder [9A60] [24]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Trandolapril and Drospirenone. Contraceptive management [QA21] [25]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Trandolapril and Ardeparin. Coronary thrombosis [BA43] [10]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Trandolapril and Selegiline. Depression [6A70-6A7Z] [21]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Trandolapril and Isocarboxazid. Depression [6A70-6A7Z] [21]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Trandolapril and OPC-34712. Depression [6A70-6A7Z] [22]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Trandolapril and Phenelzine. Depression [6A70-6A7Z] [21]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Trandolapril and Nitroglycerin. Diabetic foot ulcer [BD54] [19]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Trandolapril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [16]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Trandolapril and Ethacrynic acid. Essential hypertension [BA00] [26]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Trandolapril and Phenoxybenzamine. Essential hypertension [BA00] [12]
Benzthiazide DMQWZ0H Moderate Additive hypotensive effects by the combination of Trandolapril and Benzthiazide. Essential hypertension [BA00] [13]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Trandolapril and Acetazolamide. Glaucoma [9C61] [13]
Methazolamide DM7J2TA Moderate Additive hypotensive effects by the combination of Trandolapril and Methazolamide. Glaucoma [9C61] [13]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Trandolapril and Dichlorphenamide. Glaucoma [9C61] [26]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Trandolapril and Eplerenone. Heart failure [BD10-BD1Z] [27]
Chlorothiazide DMLHESP Moderate Additive hypotensive effects by the combination of Trandolapril and Chlorothiazide. Heart failure [BD10-BD1Z] [13]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Trandolapril and Furosemide. Heart failure [BD10-BD1Z] [13]
Amiloride DMRTSGP Major Increased risk of hyperkalemia by the combination of Trandolapril and Amiloride. Heart failure [BD10-BD1Z] [28]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Trandolapril and Bumetanide. Heart failure [BD10-BD1Z] [13]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Trandolapril and Procarbazine. Hodgkin lymphoma [2B30] [21]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [29]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [30]
Didanosine DMI2QPE Minor Decreased absorption of Trandolapril due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [16]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Trandolapril and Isosorbide mononitrate. Hydrocephalus [8D64] [19]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Trandolapril and Mipomersen. Hyper-lipoproteinaemia [5C80] [31]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Trandolapril and Teriflunomide. Hyper-lipoproteinaemia [5C80] [32]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Trandolapril and BMS-201038. Hyper-lipoproteinaemia [5C80] [33]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Trandolapril and Potassium chloride. Hypo-kalaemia [5C77] [34]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Trandolapril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [35]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Trandolapril and Propiomazine. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Trandolapril and ITI-007. Insomnia [7A00-7A0Z] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Methotrexate. Leukaemia [2A60-2B33] [36]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [37]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Idelalisib. Mature B-cell leukaemia [2A82] [38]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Trandolapril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [32]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Trandolapril and Ozanimod. Multiple sclerosis [8A40] [21]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Trandolapril and Promethazine. Nausea/vomiting [MD90] [22]
Metolazone DMB39LO Moderate Additive hypotensive effects by the combination of Trandolapril and Metolazone. Oedema [MG29] [13]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Trandolapril and Polythiazide. Oedema [MG29] [13]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Trandolapril and Safinamide. Parkinsonism [8A00] [21]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Trandolapril and Rasagiline. Parkinsonism [8A00] [21]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Trandolapril and Terazosin. Prostate hyperplasia [GA90] [12]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Trandolapril and Silodosin. Prostate hyperplasia [GA90] [12]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Trandolapril and Levomepromazine. Psychotic disorder [6A20-6A25] [22]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Trandolapril and Fluphenazine. Psychotic disorder [6A20-6A25] [22]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Trandolapril and Leflunomide. Rheumatoid arthritis [FA20] [32]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Trandolapril and Quetiapine. Schizophrenia [6A20] [22]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Trandolapril and Mesoridazine. Schizophrenia [6A20] [22]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Trandolapril and Thioridazine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Trandolapril and Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Trandolapril and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Trandolapril and Paliperidone. Schizophrenia [6A20] [22]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Trandolapril and Molindone. Schizophrenia [6A20] [22]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Trandolapril and Thiothixene. Schizophrenia [6A20] [22]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Trandolapril and Trifluoperazine. Schizophrenia [6A20] [22]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Trandolapril and Risperidone. Schizophrenia [6A20] [22]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Trandolapril and Amisulpride. Schizophrenia [6A20] [22]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Trandolapril and Asenapine. Schizophrenia [6A20] [22]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [36]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Trandolapril and Naltrexone. Substance abuse [6C40] [39]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Trandolapril and Tacrolimus. Transplant rejection [NE84] [40]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Tolbutamide. Type 2 diabetes mellitus [5A11] [17]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Chlorpropamide. Type 2 diabetes mellitus [5A11] [17]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [17]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Trandolapril and Insulin degludec. Type-1/2 diabete [5A10-5A11] [17]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Trandolapril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [41]
⏷ Show the Full List of 81 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trandolapril 1 mg tablet 1 mg Oral Tablet Oral
Trandolapril 2 mg tablet 2 mg Oral Tablet Oral
Trandolapril 4 mg tablet 4 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Trandolapril FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6453).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
8 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
9 Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. J Clin Pharm Ther. 2006 Apr;31(2):139-47. doi: 10.1111/j.1365-2710.2006.00606.x.
10 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
11 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
12 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
13 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
14 Product Information. Micardis (telmisartan). Boehringer-Ingelheim, Ridgefield, CT.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
17 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
18 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
19 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
25 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
26 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
27 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
28 Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
29 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
30 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
31 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
32 Canadian Pharmacists Association.
33 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
34 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
35 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
36 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
38 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
39 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
40 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
41 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.